» Articles » PMID: 35525274

Nuclear Focal Adhesion Kinase Induces APC/C Activator Protein CDH1-mediated Cyclin-dependent Kinase 4/6 degradation and Inhibits Melanoma Proliferation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2022 May 7
PMID 35525274
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulation of cyclin-dependent kinases (CDKs) can promote unchecked cell proliferation and cancer progression. Although focal adhesion kinase (FAK) contributes to regulating cell cycle progression, the exact molecular mechanism remains unclear. Here, we found that FAK plays a key role in cell cycle progression potentially through regulation of CDK4/6 protein expression. We show that FAK inhibition increased its nuclear localization and induced G1 arrest in B16F10 melanoma cells. Mechanistically, we demonstrate nuclear FAK associated with CDK4/6 and promoted their ubiquitination and proteasomal degradation through recruitment of CDC homolog 1 (CDH1), an activator and substrate recognition subunit of the anaphase-promoting complex/cyclosome E3 ligase complex. We found the FAK N-terminal FERM domain acts as a scaffold to bring CDK4/6 and CDH1 within close proximity. However, overexpression of nonnuclear-localizing mutant FAK FERM failed to function as a scaffold for CDK4/6 and CDH1. Furthermore, shRNA knockdown of CDH1 increased CDK4/6 protein expression and blocked FAK inhibitor-induced reduction of CDK4/6 in B16F10 cells. In vivo, we show that pharmacological FAK inhibition reduced B16F10 tumor size, correlating with increased FAK nuclear localization and decreased CDK4/6 expression compared with vehicle controls. In patient-matched healthy skin and melanoma biopsies, we found FAK was mostly inactive and nuclear localized in healthy skin, whereas melanoma lesions showed increased active cytoplasmic FAK and elevated CDK4 expression. Taken together, our data demonstrate that FAK inhibition blocks tumor proliferation by inducing G1 arrest, in part through decreased CDK4/6 protein stability by nuclear FAK.

Citing Articles

Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma.

Zhang Y, Ojalill M, Boyer A, Chen X, Tahon E, Thivolle Lioux G Cancer Res Commun. 2024; 4(12):3165-3179.

PMID: 39585085 PMC: 11659947. DOI: 10.1158/2767-9764.CRC-24-0382.


Activation of the Anaphase Promoting Complex Restores Impaired Mitotic Progression and Chemosensitivity in Multiple Drug-Resistant Human Breast Cancer.

Lubachowski M, VanGenderen C, Valentine S, Belak Z, Davies G, Arnason T Cancers (Basel). 2024; 16(9).

PMID: 38730707 PMC: 11083742. DOI: 10.3390/cancers16091755.


CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.

Nasser A, Melamed L, Wetzel E, Chang J, Nagashima H, Kitagawa Y Clin Cancer Res. 2024; 30(14):2996-3005.

PMID: 38718141 PMC: 11250907. DOI: 10.1158/1078-0432.CCR-24-0562.


Roles and inhibitors of FAK in cancer: current advances and future directions.

Hu H, Wang S, Shang H, Lv H, Chen B, Gao S Front Pharmacol. 2024; 15:1274209.

PMID: 38410129 PMC: 10895298. DOI: 10.3389/fphar.2024.1274209.


Ubiquitin-proteasome system as a target for anticancer treatment-an update.

Kim Y, Lee Y, Shin H, Hwang S, Park J, Song E Arch Pharm Res. 2023; 46(7):573-597.

PMID: 37541992 DOI: 10.1007/s12272-023-01455-0.

References
1.
Ruas M, Brookes S, McDonald N, Peters G . Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene. 1999; 18(39):5423-34. DOI: 10.1038/sj.onc.1202918. View

2.
Robert C, Ribas A, Schachter J, Arance A, Grob J, Mortier L . Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019; 20(9):1239-1251. DOI: 10.1016/S1470-2045(19)30388-2. View

3.
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V . BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012; 30(20):2522-9. DOI: 10.1200/JCO.2011.41.2452. View

4.
Jeong K, Murphy J, Ahn E, Lim S . FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation. Cardiovasc Res. 2021; 118(4):1150-1163. PMC: 8930076. DOI: 10.1093/cvr/cvab132. View

5.
Malumbres M . Cyclin-dependent kinases. Genome Biol. 2014; 15(6):122. PMC: 4097832. DOI: 10.1186/gb4184. View